February 13, 2025 - Qingdao Baheal Pharma Co., Ltd. (hereinafter referred to as "Baheal Medical," 301015.SZ), a leading pharmaceutical industrialization platform, has announced a new commercial collaboration with Shanghai Roche Pharmaceuticals Ltd. ("Roche Pharmaceuticals China").

The Ministry of Science and Technology recently announced projects under the "14th Five-Year Plan" National Key R&D Program, prioritizing "Diagnostic Equipment and Biomedical Materials." Notably, for the first time, cardiac radiotherapy technology has been included as a focus area. The project "Development of Stereotactic Radiotherapy Technology and Prototype for Cardiac Arrhythmia," led by Huake Pioneer, a medical linear accelerator developer, was successfully selected.

and 3D Disease Modeling Joint Laboratory On December 18, 2024, the "High-Quality Development Forum" was hosted by the Institute of Advanced Clinical Medicine at Peking University (IACM). During the event, Baheal's invested enterprise, CAIUSLY Technology Co., Ltd. (CAIUSLY), signed an agreement with IACM to co-establish the "Organ-on-a-Chip and 3D Disease Modeling Joint Laboratory".

Recently, renowned global growth consulting firm Frost & Sullivan (Sullivan) officially published the “2024 Blue Book on Current Status and Trends of the Conjugated Drugs Industry”. This report provides a comprehensive analysis of the industry, examining technical pathways, innovation models, development pipelines, and investment trends. It also offers insightful projections on future directions and potential opportunities within the sector. Thanks to their remarkable technological innovations and breakthroughs in the conjugated drugs field, two companies invested in by Baheal Pharma Group—Radiopharma and Rabpharma—have been highlighted as exemplary case studies in the Blue Book.

On November 25, 2024, BrioHealth Solutions, Inc., a wholly-owned BrioHealth's U.S. subsidiary, announced its independently developed fully magnetic levitation left ventricular assist device, BrioVAD®, had successful completed the first patient enrollment of the INNOVATE clinical trial at Emory University Hospital.